Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 7.16 -0.42% -0.03
BCRX closed down 0.42 percent on Friday, October 19, 2018, on approximately normal volume. It ran into resistance at its 50 day moving average. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.

Earnings due: Nov 6

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Flat Up
See historical BCRX trend table...

Date Alert Name Type % Chg
Oct 19 50 DMA Resistance Bearish 0.00%
Oct 19 Shooting Star Candlestick Bearish 0.00%
Oct 19 Lizard Bearish Bearish Day Trade Setup 0.00%
Oct 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Oct 19 20 DMA Support Bullish 0.00%
Oct 19 Doji - Bearish? Reversal 0.00%
Oct 18 50 DMA Resistance Bearish -0.42%
Oct 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.42%
Oct 18 20 DMA Support Bullish -0.42%
Oct 18 MACD Bullish Signal Line Cross Bullish -0.42%

Older signals for BCRX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Is BCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 8.13
52 Week Low 4.12
Average Volume 550,034
200-Day Moving Average 5.8837
50-Day Moving Average 7.1938
20-Day Moving Average 7.125
10-Day Moving Average 6.939
Average True Range 0.3347
ADX 21.54
+DI 19.3738
-DI 18.6589
Chandelier Exit (Long, 3 ATRs ) 6.7259
Chandelier Exit (Short, 3 ATRs ) 7.4341
Upper Bollinger Band 7.7512
Lower Bollinger Band 6.4988
Percent B (%b) 0.53
BandWidth 17.577544
MACD Line -0.0252
MACD Signal Line -0.0437
MACD Histogram 0.0185
Fundamentals Value
Market Cap 575.86 Million
Num Shares 80.4 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -11.55
Price-to-Sales 11.43
Price-to-Book 13.91
PEG Ratio -0.28
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.79
Resistance 3 (R3) 7.83 7.67 7.69
Resistance 2 (R2) 7.67 7.51 7.65 7.65
Resistance 1 (R1) 7.41 7.41 7.33 7.37 7.61
Pivot Point 7.25 7.25 7.21 7.23 7.25
Support 1 (S1) 6.99 7.09 6.91 6.95 6.71
Support 2 (S2) 6.83 6.99 6.81 6.67
Support 3 (S3) 6.57 6.83 6.64
Support 4 (S4) 6.53